6 news items
Alkermes Unveils Phase 1b Data for Narcolepsy Treatment at SLEEP 2024
ALKS
3 Jun 24
1b study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 via once-daily, single, oral administration
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
ALKS
3 Jun 24
.
The phase 1b study evaluated the safety, tolerability, pharmacokinetics
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
ALKS
28 May 24
1b, proof-of-concept study evaluating single dose oral administration of ALKS 2680. Safety results and pharmacodynamic efficacy assessments evaluating
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
ALKS
28 May 24
, proof-of-concept study evaluating single dose oral administration of ALKS 2680. Safety results and pharmacodynamic efficacy assessments evaluating
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
ALKS
14 May 24
̶ Results from Long-Term Safety Study and Data from
74y7lrzzeradpgb925t6ca77jwnct32azbai
ALKS
1 May 24
.In April 2024, the company presented data from its long-term safety study of LYBALVI (olanzapine and samidorphan
- Prev
- 1
- Next